MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

NCT01085331 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
16
Enrollment
INDUSTRY
Sponsor class

Stopped Conduct the randomized Phase 2 part not recommended due to the achieved MTD for pimasertib (45mg/day) in combination with FOLFIRI

Conditions

Interventions

Sponsor

EMD Serono